Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Community Corner
  • Published:

Semagacestat's fall: where next for AD therapies?

Nature Medicine volume 19, pages 1214–1215 (2013)Cite this article

Subjects

Kaj Blennow & Henrik Zetterberg

This clinical trial testing semagacestat1, a drug that lowers γ-secretase–mediated Aβ production, as an AD-modifying treatment adds to the growing list of failures of anti-Aβ therapies. The key question is whether the lack of effect on cognition, and even the worsening of daily function1, observed in the trial was related to semagacestat as a molecule, γ-secretase inhibitors as a principle, the design of the trial or a combination of these factors.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Doody, R.S. et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N. Engl. J. Med. 369, 341–350 (2013).

    Article  CAS  Google Scholar 

  2. Fleisher, A.S. et al. Phase 2 safety trial targeting amyloid b production with a γ-secretase inhibitor in Alzheimer disease. Arch. Neurol. 65, 1031–1038 (2008).

    Article  Google Scholar 

  3. Portelius, E. et al. A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer's disease. Alzheimers Res. Ther. 2, 7 (2010).

    Article  Google Scholar 

  4. Scheuner, D. et al. Secreted amyloid b-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2, 864–870 (1996).

    Article  CAS  Google Scholar 

  5. Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131–144 (2010).

    Article  CAS  Google Scholar 

  6. Levitan, D. & Greenwald, I. Facilitation of lin-12–mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature 377, 351–354 (1995).

    Article  CAS  Google Scholar 

  7. Xia, X. et al. Loss of presenilin 1 is associated with enhanced b-catenin signaling and skin tumorigenesis. Proc. Natl. Acad. Sci. USA 98, 10863–10868 (2001).

    Article  CAS  Google Scholar 

  8. van Es, J.H. et al. Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435, 959–963 (2005).

    Article  CAS  Google Scholar 

  9. Wong, G.T. et al. Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits b-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279, 12876–12882 (2004).

    Article  CAS  Google Scholar 

  10. Kuhn, P.H. et al. Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J. 31, 3157–3168 (2012).

    Article  CAS  Google Scholar 

  11. Willem, M. et al. Control of peripheral nerve myelination by the b-secretase BACE1. Science 314, 664–666 (2006).

    Article  CAS  Google Scholar 

  12. Cheret, C. et al. Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles. EMBO J. 32, 2015–2028 (2013).

    Article  CAS  Google Scholar 

  13. Jonsson, T. et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96–99 (2012).

    Article  CAS  Google Scholar 

  14. Savva, G.M. et al. Age, neuropathology, and dementia. N. Engl. J. Med. 360, 2302–2309 (2009).

    Article  CAS  Google Scholar 

  15. Holmes, C. et al. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216–223 (2008).

    Article  CAS  Google Scholar 

  16. Orgogozo, J.-M. et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61, 46–54 (2003).

    Article  CAS  Google Scholar 

Download references

Ethics declarations

Competing interests

K.B. has served on advisory boards for Innogenetics, Lilly, Pfizer and Roche. The other authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Semagacestat's fall: where next for AD therapies?. Nat Med 19, 1214–1215 (2013). https://doi.org/10.1038/nm.3365

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.3365

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing